Shorter radiation shows promise for prostate cancer control
NCT ID NCT07489729
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two radiation therapy schedules for men with intermediate- or high-risk prostate cancer. One group received fewer, higher-dose radiation sessions (hypofractionated), while the other received standard daily doses. Both groups also received hormone therapy. The goal was to see which approach better controlled cancer and reduced side effects. The study involved 60 men and measured PSA levels, tumor response, and survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOFRACTIONATED DOSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
Tanta, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a better scan sharpen radiation for prostate cancer?
- Can a single radiation type spare prostate cancer patients from extra side effects?
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?
- Can a Triple-Drug cocktail before surgery curb prostate Cancer's return?